| Literature DB >> 23891512 |
Jangchul Park1, Kimihide Yoshida1, Chiaki Kondo1, Junichi Shimizu1, Yoshitsugu Horio1, Susumu Hijioka2, Toyoaki Hida3.
Abstract
This report describes esophageal ulcer as a novel adverse event associated with crizotinib therapy. Although crizotinib is generally well tolerated, physicians should be aware of the possibility of this adverse event.Entities:
Keywords: Adverse event; Anaplastic lymphoma kinase; Crizotinib; Inhibitor; Non-small-cell lung cancer; Ulceration
Mesh：
Substances：
Year: 2013 PMID： 23891512 DOI： 10.1016/j.lungcan.2013.06.017
Source DB: PubMed Journal: Lung Cancer ISSN： 0169-5002 Impact factor: 5.705